CVS Beats on Revenue and EPS, Lifts 2026 Guidance, Confirms Two-Company Split
CVS sits 34% above its 52-week low of $69.51 on elevated volume (2.4× avg).
Summary
CVS delivered a clean beat: Q3 revenue of $108.40 billion against a $104.69 billion consensus, and adjusted EPS of $2.09 versus $1.65 expected. Management raised full-year 2026 adjusted EPS guidance to at least $8.20 from $7.90-$8.10 and lifted cash flow from operations guidance to at least $15.5 billion from $11.5 billion — the cash flow jump is the biggest surprise in the release. The company also confirmed it will separate into two independent public companies, a healthcare solutions business and CVS Pharmacy, following yesterday's report that a retail pharmacy spin-off was under discussion. Segment detail explains the quarter: Health Services revenue rose 9.5% and Health Care Benefits adjusted operating income improved on the government business, while Pharmacy & Consumer Wellness revenue fell 2.0% on regulatory price reductions and reimbursement pressure — precisely the unit now being carved out. The split is targeted for the first half of 2028, so the near-term trade is the guidance raise, not the separation mechanics.
At the time of this announcement, CVS was trading at $93.20 on NYSE in the Trade & Services sector, with a market capitalization of approximately $116.9B. The 52-week trading range was $69.51 to $110.68. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.